Dr. Jean Bennett, M.D., Ph.D. is a Scientific Co-Founder and Advisor at Spark Therapeutics, LLC. Dr. Bennett serves as Scientific Founder and Vice Chairman of Scientific Advisory Board of GenSight Biologics SA and has been its Member of Scientific Advisory Board since April 17, 2012. She serves as a Member of Scientific Advisory Board at Adverum Biotechnologies, Inc. (also known as Avalanche Biotechnologies, Inc). Dr. Bennett is the F.M. Kirby Professor of Ophthalmology at the University of Pennsylvania and is a renowned expert in gene therapy, animal models and translational medicine in retinal disease. Dr. Bennett studies the molecular genetics of inherited retinal degenerations with the idea of using this knowledge to develop rational approaches for treatment of these diseases and reversal of sensory loss. She serves as Member of Scientific Advisory Board of SparingVision SAS. In particular, her work has focused on retinitis pigmentosa and related blinding conditions. She was one of the first investigators to use viral vectors to deliver transgenes to specific cells in the retina and also led the first team to demonstrate preclinical proof-of-principle of ocular gene therapy. Besides diseases of the eye, her laboratory targets other diseases/organs suffering from mutations in cilia proteins, including the ear and the kidney. She is active with a variety of national and international organizations promoting translational research including the Association for Research in Vision and Opthalmology and the American Society of Cell and Gene Therapy. She has received several awards, including the Paul Kayser International Award in Retina Research, the Alfred W. Bressler Prize in Vision Research and the William Osler Award for Translational Research. She received her B.S. in biology from Yale University, her Ph.D. in zoology and cell and developmental biology from the University of California at Berkley and her M.D. from Harvard Medical School.